Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results cover the period ended March 31, 2026.
Dianthus Therapeutics, Inc. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results cover the period ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results
- Disclosure is furnished, not filed under Exchange Act Section 18, limiting associated liability exposure
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $0.5M and net loss $40.8M, or $0.85 per share, reflecting continued clinical-stage cash burn
- Cash, equivalents and investments $1.2B at March 31, 2026, extending projected runway into 2030
- CAPTIVATE early GO decision after 20 confirmed responders, accelerating confidence in claseprubart’s CIDP development
- Claseprubart Phase 3 gMG trial remains on track for mid-2026 start, with top-line results expected in 2H’28
- $719M gross equity offering strengthens funding but increases potential shareholder dilution; DNTH212 Phase 1 data expected in 2H’26
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dianthus Therapeutics, Inc. /DE/ 8-K filings
Get the next DNTH 8-K as it lands
Follow DNTH for push alerts, or ask the research agent what this filing means.